CareDx, Inc. (Nasdaq: CDNA) will report its second-quarter 2026 financial results after the United States market closes on Thursday, July 30, followed by a webcast and conference call at 1:30 p.m. Pacific Time and 4:30 p.m. Eastern Time. Although the July 16 announcement contained no preliminary financial figures, it establishes the timetable for a report that will test whether CareDx’s recent operational momentum can support a dramatic rerating of its shares.
The earnings call arrives after one of the most consequential periods in CareDx’s recent history. Since reporting its first-quarter results, the precision diagnostics company has completed the sale of its Lab Products business to Eurobio Scientific, closed the acquisition of Naveris, expanded into viral-mediated cancer monitoring and received clarity on Medicare coverage for molecular surveillance testing after solid organ transplantation.
CareDx shares closed at $37.76 on July 22, down 2.01% for the session but approximately 27% above their July 15 close and about 51% above the June 22 closing price of $25.05. The stock has roughly doubled from its $18.84 level at the beginning of 2026 and remains close to its recently established 52-week high of $40.47. The sharpest move occurred on July 16, when the shares rose 35.6% as the final Medicare coverage policy reduced a major reimbursement uncertainty surrounding the transplant testing franchise.
Why is CareDx’s July 30 earnings report more consequential than a routine calendar notice?
The second-quarter results will provide the first detailed financial checkpoint since CareDx began repositioning itself from a transplant-focused diagnostics company into a broader precision medicine platform spanning transplantation, specialty oncology and cell therapy. That expansion may increase the company’s addressable market, but it also introduces integration, capital-allocation and execution risks that were not central to the investment case only a few months ago.
Management entered the quarter with unusually strong reported momentum. First-quarter revenue reached $117.7 million, an increase of 39% from $84.7 million a year earlier. Testing services revenue climbed 48% to approximately $91 million, while testing volume increased 17% to about 54,900 tests. Patient and digital solutions revenue rose 33% to $16 million, although Lab Products revenue declined 4% to approximately $10 million.
The stronger revenue mix and operating leverage allowed CareDx to report GAAP net income of approximately $3 million, compared with a $10 million loss in the prior-year quarter. Adjusted EBITDA increased to $19 million from $5 million, prompting management to raise full-year 2026 revenue guidance to between $447 million and $465 million and adjusted EBITDA guidance to between $43 million and $57 million.
Those figures created a high starting point for the year. The July 30 report must therefore demonstrate that the first quarter represented more than a favourable combination of volume growth, revenue mix and improved cash collections.
Can testing services growth remain strong after first-quarter revenue benefited from prior-period collections?
CareDx’s first-quarter testing services performance was supported by both higher test volumes and approximately $14 million of revenue related to tests performed in earlier periods. That prior-period contribution increased average revenue per test to approximately $1,660 and made reported year-over-year growth unusually strong.
The second-quarter report should make it easier to separate sustainable operating growth from collections-related timing effects. Investors will be looking for testing volumes, average revenue per test, current-period collections and any further adjustments involving tests performed in earlier quarters.
Volume may be the cleanest operating indicator. CareDx processed approximately 49,500 testing services results in the second quarter of 2025, up 13% year over year, with AlloSure Kidney volumes increasing nearly 20%. Reported second-quarter 2025 revenue was $86.7 million, but that figure included a $3.8 million write-off involving aged receivables. CareDx presented adjusted revenue of $90.5 million after excluding that item.
This creates a comparatively low reported revenue base for the second quarter of 2026, potentially producing a strong headline growth rate. However, an impressive percentage increase will not by itself establish that underlying economics have improved. The more informative questions concern whether testing volume has continued rising at a double-digit rate, whether collection performance has remained stable and whether reimbursement per test is becoming more predictable.
CareDx has also been increasing integrations with hospital technology systems. At the end of the first quarter, nine transplant centres were live with Epic Aura integrations and another 16 integrations were in process. These integrations may make ordering and managing molecular tests easier within clinical workflows, but the July 30 update will need to show whether deployment progress is beginning to influence utilisation or customer retention.
How will the final Medicare policy change expectations for AlloSure and AlloMap growth?
The most important development preceding the earnings report is the final Medicare Local Coverage Determination for molecular testing used in solid organ allograft rejection. The policy is scheduled to become effective for services performed on or after August 30, 2026, meaning it will not affect CareDx’s reported second-quarter revenue. Its importance is prospective rather than retrospective.
For kidney transplantation, the policy supports surveillance testing with AlloSure Kidney for up to six tests during the first year after transplantation and up to four tests annually during years two and three. CareDx has reported that patients receiving AlloSure Kidney currently average approximately three to four tests during the first post-transplant year, suggesting potential room for increased utilisation within the covered cadence.
For heart transplantation, coverage continues for AlloMap and AlloSure Heart, including combined use when medically appropriate. The policy permits up to 12 surveillance tests in the first year and four annually during years two and three. AlloSure Lung is similarly covered for up to 12 tests during the first year and four tests annually in years two and three. Coverage for clinically indicated, for-cause testing remains available across the named transplant categories.
The policy provides commercial clarity, but it should not be interpreted as an automatic volume guarantee. The Medicare framework requires tests to satisfy analytical validity, clinical validity and clinical utility requirements. It also limits each patient encounter to one molecular test for assessing allograft status unless a combined test demonstrates appropriate additive value. Ordering physicians must use the results to inform clinical decisions alongside other assessments.
The July 30 call should therefore focus less on celebrating the coverage decision and more on explaining implementation. Investors need to understand how quickly transplant centres may adjust surveillance protocols, whether physician education will be required, how the policy affects expected testing cadence and when any resulting revenue impact could become visible.
What will the Eurobio divestiture and Naveris acquisition reveal about CareDx’s new model?
CareDx completed the sale of its Lab Products business to Eurobio Scientific on June 30 after obtaining the required Swedish regulatory clearance. The company received $171.2 million in cash at closing, subject to customary adjustments. The divested operation included in vitro diagnostic polymerase chain reaction kits for deceased-donor human leukocyte antigen typing, next-generation sequencing kits for recipient typing and monitoring assays marketed outside North America.
Because the transaction closed on the final day of the second quarter, the July 30 financial statements should capture the cash proceeds and transaction accounting while still including the operating contribution of the Lab Products business for most or all of the reported period. Comparability will become more difficult from the third quarter, when CareDx’s revenue mix no longer includes the divested operation.
One day after the Eurobio transaction closed, CareDx completed its acquisition of Naveris. CareDx agreed to pay $160 million in upfront cash, with up to another $100 million linked to revenue milestones. Naveris generated approximately $35 million in revenue during 2025, more than doubling year over year, while first-quarter 2026 revenue was approximately $12 million.
Naveris will be consolidated into CareDx’s financial results beginning in the third quarter, meaning the second-quarter numbers will not yet contain revenue from its NavDx test. However, the July 30 earnings call should provide an early indication of integration priorities, commercial plans and updated full-year guidance.
NavDx is a blood-based molecular residual disease test designed to detect and monitor tumour tissue modified viral DNA in human papillomavirus-associated head and neck and anal cancers. CareDx has said that more than 130,000 tests have been commercially reported and that NavDx has a Medicare Advanced Diagnostic Laboratory Test reimbursement rate of $1,800.
The acquisition moves CareDx into a faster-growing but highly competitive oncology diagnostics market. The strategic logic rests on similarities between transplant surveillance and cancer monitoring, including longitudinal testing, specialist-led adoption, reimbursement evidence and repeat use over time. The commercial test is whether CareDx can apply its existing capabilities without distracting management from the transplant franchise that currently supplies most of its testing revenue.
Can CareDx preserve margin momentum while funding oncology expansion and integration?
CareDx’s first-quarter adjusted EBITDA of $19 million represented a substantial improvement from $5 million a year earlier. The company also generated approximately $4 million of operating cash flow and reported a non-GAAP gross margin of 73%, compared with 68% in the prior-year quarter.
Management previously indicated that the Naveris acquisition was expected to be neutral to CareDx’s full-year 2026 adjusted EBITDA guidance. That expectation will now face scrutiny because integration costs, commercial investment and transaction expenses can affect the pace at which an acquired diagnostics business contributes to earnings.
The disposal and acquisition also create a cleaner but more concentrated operating model. CareDx has exchanged a global laboratory-products operation for a United States-focused precision diagnostics strategy built around higher-value testing services. In principle, this could improve recurring revenue, gross margins and strategic focus. In practice, success will depend on disciplined spending and the company’s ability to expand adoption without allowing sales, research and administrative expenses to grow faster than sustainable revenue.
Research and development spending increased to approximately $21.4 million during the first quarter of 2026 from $18.5 million a year earlier. Sales and marketing expenses increased to about $30.4 million from $23 million, while general and administrative expenses rose to approximately $31.1 million from $28.1 million. These increases were absorbed by revenue growth in the first quarter, but the July 30 report must show that operating leverage is continuing.
What does CareDx’s 2026 stock surge imply about the burden of proof on management?
CareDx’s market sentiment has changed rapidly. At $37.76 on July 22, the shares were approximately 100% above their price at the beginning of 2026 and about 236% above the lower end of their recent 52-week trading range. The company’s market capitalisation has moved to roughly $2 billion, compared with less than $1 billion at the end of 2025.
The rerating reflects several developments rather than the scheduling of the earnings call itself. First-quarter revenue exceeded market expectations, the Lab Products disposal released substantial cash, Naveris added an oncology growth platform and the Medicare decision reduced reimbursement uncertainty. The July 16 coverage announcement coincided with a 35.6% single-session share-price increase on unusually heavy trading volume.
That enthusiasm also raises the burden of proof. At the beginning of the year, CareDx was valued primarily as a recovering transplant diagnostics company. The current share price increasingly assumes that management can maintain strong transplant testing growth, convert Medicare clarity into higher utilisation, integrate Naveris successfully and deliver margin expansion.
A satisfactory quarter may therefore require more than beating a revenue estimate. Investors are likely to focus on the quality of growth, the proportion generated by current-period testing, the outlook for adjusted EBITDA and whether full-year guidance reflects the company’s post-transaction structure.
Which disclosures on July 30 will determine whether the CareDx rerating remains credible?
The most consequential figures will be testing services volume, average revenue per test, current-period revenue, adjusted EBITDA and updated full-year guidance. Management’s explanation of prior-period revenue and collection trends will be especially important because these items have created volatility in reported revenue during recent quarters.
The market will also expect a clear bridge between the old and new CareDx. The Lab Products business closed on June 30, while Naveris entered the group on July 1. Investors will need enough information to understand the revenue and margin contribution being removed, the contribution being added and the costs required to integrate the oncology operation.
The Medicare coverage decision has already altered market expectations, but its financial contribution should emerge only after the policy becomes effective on August 30. Any immediate increase in 2026 guidance attributed to the policy would therefore need to be explained carefully, including assumptions around test cadence, transplant-centre adoption and the timing of claims.
CareDx’s July 30 results will not determine the clinical value of its molecular diagnostics portfolio. They will determine whether the company is converting adoption, reimbursement clarity and strategic transactions into a financially durable precision diagnostics platform. After the stock’s rapid rise, management must now show that the business is advancing as quickly as the valuation.
